{"hands_on_practices": [{"introduction": "Understanding the precise molecular mechanism of inhibition is the cornerstone of enzyme kinetics. This exercise challenges a common misconception about competitive inhibitors, forcing you to distinguish their unique binding pattern—to the free enzyme at the active site—from other forms of inhibition. Mastering this fundamental concept is crucial before moving on to quantitative analysis. [@problem_id:2071783]", "problem": "A biochemistry student is investigating the kinetics of an enzyme that follows the Michaelis-Menten model. The student aims to characterize a newly synthesized compound, Compound X, which is hypothesized to be a competitive inhibitor of the enzyme. To explain the expected experimental outcome, the student formulates a hypothesis about the inhibitor's mechanism of action:\n\n\"My hypothesis is that Compound X acts as a competitive inhibitor by binding directly to the enzyme-substrate (ES) complex. This binding event forms a non-productive enzyme-substrate-inhibitor (ESI) ternary complex, which sequesters the enzyme and prevents the formation of the product.\"\n\nAnalyze the student's hypothesis. Which of the following statements most accurately identifies the fundamental flaw in the student's understanding of the mechanism of competitive inhibition?\n\nA. The inhibitor does not bind to the enzyme at all; it binds directly to the substrate in the solution, rendering the substrate unable to bind to the enzyme's active site.\n\nB. The inhibitor binds to an allosteric site on the free enzyme, which is a regulatory site distinct from the active site, thereby inducing a conformational change that reduces the enzyme's activity.\n\nC. The inhibitor does not bind to the enzyme-substrate (ES) complex. Instead, it binds reversibly to the active site of the free enzyme, directly competing with the substrate.\n\nD. The inhibitor binds to the enzyme-substrate (ES) complex, but it does so irreversibly through the formation of a covalent bond, permanently inactivating the enzyme.\n\nE. The inhibitor binds to the enzyme-substrate (ES) complex as proposed, but its effect is to increase the catalytic rate, not prevent product formation.", "solution": "The student claims that a competitive inhibitor binds the enzyme-substrate complex to form a nonproductive ternary complex ESI. Begin with the Michaelis-Menten baseline:\n$$\nE + S \\rightleftharpoons ES \\xrightarrow{k_{2}} E + P,\n$$\nwith $K_{M} = \\frac{k_{-1} + k_{2}}{k_{1}}$ and initial rate\n$$\nv = \\frac{V_{\\max}[S]}{K_{M} + [S]}, \\quad V_{\\max} = k_{2}[E]_{\\text{total}}.\n$$\n\nFor competitive inhibition, the defining mechanistic feature is reversible binding of inhibitor to the free enzyme at the active site, directly competing with substrate:\n$$\nE + I \\rightleftharpoons EI \\quad \\text{with} \\quad K_{I} = \\frac{k_{-1}^{I}}{k_{1}^{I}},\n$$\nand no binding to $ES$. The resulting rate law is\n$$\nv = \\frac{V_{\\max}[S]}{\\alpha K_{M} + [S]}, \\quad \\alpha = 1 + \\frac{[I]}{K_{I}},\n$$\nwhich shows $V_{\\max}$ unchanged and the apparent $K_{M}$ increased to $\\alpha K_{M}$.\n\nBy contrast, an inhibitor that binds the enzyme-substrate complex forms an ESI complex:\n$$\nES + I \\rightleftharpoons ESI \\quad \\text{with} \\quad K_{I}' = \\frac{k_{-1}'}{k_{1}'},\n$$\nleading to uncompetitive inhibition with rate law\n$$\nv = \\frac{V_{\\max}[S]}{K_{M} + \\alpha'[S]}, \\quad \\alpha' = 1 + \\frac{[I]}{K_{I}'},\n$$\nwhere both $V_{\\max}$ and $K_{M}$ decrease by the factor $\\frac{1}{\\alpha'}$. Mixed inhibition arises if inhibitor binds both $E$ and $ES$.\n\nTherefore, the student’s description (binding to $ES$ to form a nonproductive ESI complex) corresponds to uncompetitive or mixed inhibition, not competitive inhibition. The fundamental flaw is asserting that a competitive inhibitor binds the $ES$ complex. The correct statement about competitive inhibition is that it binds reversibly to the free enzyme at the active site, directly competing with substrate and not binding to $ES$. Among the options, this is exactly captured by option C; the other options either deny enzyme binding entirely (A), assert allosteric binding inconsistent with competitive inhibition (B), invoke irreversible chemistry (D), or claim rate enhancement (E), which contradicts inhibition.\n\nHence, the correct identification of the flaw is that competitive inhibitors do not bind the $ES$ complex; they bind the free enzyme’s active site and compete with substrate.", "answer": "$$\\boxed{C}$$", "id": "2071783"}, {"introduction": "Once the mechanism of competitive inhibition is understood, the next step is to quantify its impact on enzyme kinetics. This practice focuses on the central relationship between the inhibitor concentration $[I]$, the inhibition constant $K_I$, and the resulting apparent Michaelis constant $K_{M,app}$. By working through this calculation, you will gain a practical feel for how a competitive inhibitor's potency directly influences an enzyme's affinity for its substrate. [@problem_id:2071823]", "problem": "A biochemist is investigating a new potential therapeutic agent designed to target a specific metabolic enzyme. The enzyme is known to have a Michaelis constant ($K_M$) of 5 µM for its substrate. The therapeutic agent is identified as a competitive inhibitor of this enzyme. In a series of kinetic experiments, the inhibitor is determined to have an inhibition constant ($K_I$) of 2 nM. For a subsequent assay, the biochemist prepares a reaction mixture containing a concentration of this inhibitor equal to 10 nM. Calculate the apparent Michaelis constant ($K_{M,app}$) for the enzyme under these assay conditions.\n\nExpress your answer in units of micromolar (µM).", "solution": "For competitive inhibition in Michaelis-Menten kinetics, the effect of inhibitor concentration $[I]$ with inhibition constant $K_{I}$ is to scale the Michaelis constant by the factor\n$$\n\\alpha = 1 + \\frac{[I]}{K_{I}}.\n$$\nThe apparent Michaelis constant is therefore\n$$\nK_{M,\\text{app}} = \\alpha K_{M} = \\left(1 + \\frac{[I]}{K_{I}}\\right) K_{M}.\n$$\nTo evaluate $\\alpha$, $[I]$ and $K_{I}$ must be expressed in the same concentration units. Given $[I] = 10$ nanomolar and $K_{I} = 2$ nanomolar, their ratio is\n$$\n\\frac{[I]}{K_{I}} = \\frac{10}{2} = 5,\n$$\nso\n$$\n\\alpha = 1 + 5 = 6.\n$$\nWith $K_{M} = 5$ micromolar, the apparent Michaelis constant is\n$$\nK_{M,\\text{app}} = 6 \\times 5 = 30\n$$\nin micromolar units.", "answer": "$$\\boxed{30}$$", "id": "2071823"}, {"introduction": "Bridging theory and practice, this final exercise simulates a real-world biochemical investigation where you must determine an inhibitor's potency from raw kinetic data. Unlike problems with pre-defined constants, here you will analyze experimental measurements to first find the enzyme's intrinsic properties ($V_{max}$ and $K_M$) and then calculate the inhibitor constant, $K_I$. This comprehensive analysis hones the critical skills needed to characterize novel therapeutic compounds in a laboratory setting. [@problem_id:2071808]", "problem": "A clinically relevant mutant of the enzyme Phosphofructokinase-2 (PFK-2), designated PFK-2-M, is known to be overactive and contributes to unregulated metabolic pathways in a specific cell line. A novel synthetic compound, PX-784, is being evaluated as a potential therapeutic agent by characterizing its effect on the enzyme's kinetics.\n\nA series of kinetic experiments were performed. In each experiment, the initial reaction velocity, $v_0$, was measured at various concentrations of the inhibitor PX-784, while the concentration of the substrate, fructose-6-phosphate ($[S]$), was held at a fixed value. This procedure was carried out for two different fixed concentrations of the substrate. The collected data is presented below. All concentrations are given in micromolar ($\\mu$M), and the velocities are in nanomoles per second ($\\text{nmol s}^{-1}$).\n\nData for substrate concentration $[S] = 25.0$ $\\mu$M:\n| [PX-784] ($\\mu$M) | $v_0$ ($\\text{nmol s}^{-1}$) |\n|:-----------------:|:--------------------------:|\n| 0.0 | 33.3 |\n| 10.0 | 25.0 |\n| 20.0 | 20.0 |\n| 40.0 | 14.3 |\n| 60.0 | 11.1 |\n\nData for substrate concentration $[S] = 100.0$ $\\mu$M:\n| [PX-784] ($\\mu$M) | $v_0$ ($\\text{nmol s}^{-1}$) |\n|:-----------------:|:--------------------------:|\n| 0.0 | 66.7 |\n| 10.0 | 57.1 |\n| 20.0 | 50.0 |\n| 40.0 | 40.0 |\n| 60.0 | 33.3 |\n\nAssuming the data perfectly fits a standard model of reversible enzyme inhibition, calculate the inhibitor constant, $K_I$, for the compound PX-784. Express your answer in units of micromolar ($\\mu$M) and round to three significant figures.", "solution": "We assume reversible inhibition following Michaelis-Menten kinetics. For competitive inhibition, the initial velocity at fixed substrate concentration $S$ and inhibitor concentration $I$ is\n$$\nv \\;=\\; \\frac{V_{\\max}\\, S}{K_{M}\\!\\left(1+\\frac{I}{K_{I}}\\right)+S}\\,,\n$$\nwhich reduces at $I=0$ to the Michaelis-Menten form\n$$\nv \\;=\\; \\frac{V_{\\max}\\, S}{K_{M}+S}\\,.\n$$\nInspection of the data shows that at a given $I$, inhibition is weaker at the higher $S$ (for example, at $I=10$, $v$ changes from $33.3$ to $25.0$ at $S=25$, a larger fractional drop than from $66.7$ to $57.1$ at $S=100$), which is consistent with competitive inhibition and inconsistent with pure noncompetitive (which would give the same fractional inhibition at both $S$) or uncompetitive (which typically shows stronger inhibition at higher $S$). We therefore proceed with the competitive model.\n\nFirst determine $V_{\\max}$ and $K_{M}$ from the $I=0$ data. Let $(S_{1},v_{1})=(25.0,33.3)$ and $(S_{2},v_{2})=(100.0,66.7)$ (concentrations in micromolar, velocities in nanomoles per second). Then\n$$\nv_{1} \\;=\\; \\frac{V_{\\max} S_{1}}{K_{M}+S_{1}}, \n\\qquad\nv_{2} \\;=\\; \\frac{V_{\\max} S_{2}}{K_{M}+S_{2}}.\n$$\nTaking the ratio,\n$$\n\\frac{v_{2}}{v_{1}} \\;=\\; \\frac{S_{2}}{K_{M}+S_{2}} \\cdot \\frac{K_{M}+S_{1}}{S_{1}}.\n$$\nWith $S_{2}=4 S_{1}$ and $v_{2}\\approx 2 v_{1}$ (from the data), this gives\n$$\n2 \\;=\\; \\frac{4 S_{1}}{K_{M}+4S_{1}} \\cdot \\frac{K_{M}+S_{1}}{S_{1}}\n\\;\\;\\Longrightarrow\\;\\;\n2\\left(K_{M}+4S_{1}\\right) \\;=\\; 4\\left(K_{M}+S_{1}\\right)\n\\;\\;\\Longrightarrow\\;\\;\nK_{M} \\;=\\; 2 S_{1}.\n$$\nWith $S_{1}=25.0$, this yields $K_{M}=50.0$. Then from $v_{1} = V_{\\max} S_{1}/(K_{M}+S_{1})$,\n$$\nV_{\\max} \\;=\\; v_{1}\\,\\frac{K_{M}+S_{1}}{S_{1}} \\;=\\; v_{1}\\,\\frac{50.0+25.0}{25.0} \\;=\\; 3\\,v_{1}.\n$$\nUsing the tabulated value $v_{1}=33.3$, this gives $V_{\\max}\\approx 100.0$, consistent with the rounded data.\n\nFor competitive inhibition at fixed $S$, solve the velocity expression for $K_{I}$. Starting from\n$$\nv \\;=\\; \\frac{V_{\\max} S}{K_{M}\\!\\left(1+\\frac{I}{K_{I}}\\right)+S},\n$$\ncross-multiply and rearrange:\n$$\nv\\left[K_{M}\\!\\left(1+\\frac{I}{K_{I}}\\right)+S\\right] \\;=\\; V_{\\max} S\n\\;\\;\\Longrightarrow\\;\\;\nv K_{M} \\frac{I}{K_{I}} \\;=\\; V_{\\max} S - v(S+K_{M})\n\\;\\;\\Longrightarrow\\;\\;\nK_{I} \\;=\\; \\frac{I\\, v\\, K_{M}}{V_{\\max} S - v(S+K_{M})}.\n$$\nInsert $K_{M}=50.0$ and $V_{\\max}=100.0$ along with any $(S,I,v)$ triplet from the tables. For example, with $S=100.0$, $I=20.0$, $v=50.0$,\n$$\nK_{I} \\;=\\; \\frac{20.0 \\cdot 50.0 \\cdot 50.0}{100.0 \\cdot 100.0 - 50.0(100.0+50.0)}\n\\;=\\;\n\\frac{50000}{10000 - 7500}\n\\;=\\;\n\\frac{50000}{2500}\n\\;=\\;\n20.0.\n$$\nUsing other data pairs (e.g., $S=25.0$, $I=10.0$, $v=25.0$) yields the same value, confirming internal consistency. Therefore, the inhibitor constant is $K_{I}=20.0$ in micromolar units, as required.", "answer": "$$\\boxed{20.0}$$", "id": "2071808"}]}